Sling Therapeutics is an Ann Arbor, Michigan-based clinical-stage biopharmaceutical company developing linsitinib, an oral small-molecule IGF-1R inhibitor and the first and only late-stage oral therapy in development for thyroid eye disease (TED), a rare autoimmune condition affecting more than 200,000 people in the U.S. Linsitinib has an established safety profile across more than 900 patients in 15 clinical trials, met its primary endpoint in the Phase 2b/3 LIDS trial, and holds U.S. FDA Fast Track designation. The company is advancing linsitinib through the global Phase 3 ORBIT pivotal trial, backed by investors including Forbion, TPG Life Sciences Innovations and Sectoral Asset Management.
1
Round
1
Industry
5
Tags
Sep 16, 2026
Latest raise
Funding activity · 1 round
Sep 16, 2026
$123M
Series C+
Led by Forbion
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
